Contributions
Abstract: PB2316
Type: Publication Only
Background
The use of ruxolitinib, interferon alfa and cytostatic agents is aimed at improving quality of life, prevention of progression and complications in patients with primary myelofibrosis (PMF). It is quite difficult to identify what kind of therapy is the most efective in patients with prefibrotic stage of PMF
Aims
To assess the effect of different therapy regimens on the course of the disease in patients with prefibrotic stage of PMF
Methods
We analyzed 32 Jak-positive patients with PMF (diagnosed according to the World Health Organisation Classification 2016). A total of 32 patients were included in this study. The age of subject ranged from 32 to 64 years. 8 patients were males and 24 - females. The mean follow-up was 42±9 month. Bone marrow biopsy control was performed in all the patients in 31±7 month. Estimation of spleen and liver size with ultrasound was made every 6 month. Patients were divided into three groups: 8 received 6±2 courses of cladribine and then interferon alfa, 10 were treated by interferon alfa and 14 received monotherapy by hydroxycarbamid
Results
Bone marrow biopsy control showed fibrotic stage of PMF in all groups of patients. However there was difference in spleen size. Initially there was no significant difference in spleen size in all groups of patients (range 257±34 by 109±31 mm). By the end of follow-up average size of spleen were 157±24 by 64±12 mm, 167±33 by 79±27 mm and 199±21 by 92±29 in first, second and third group respectively
Conclusion
Therapy with cladribine, hydroxycarbamide and interferon alfa doesn't influence the evolution of PMF. Cladribinein patients with prefibrotic stage of PMF significantly improves the quality of life due to more effective reduction of splenomegaly.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Cladribine, Myelofibrosis
Abstract: PB2316
Type: Publication Only
Background
The use of ruxolitinib, interferon alfa and cytostatic agents is aimed at improving quality of life, prevention of progression and complications in patients with primary myelofibrosis (PMF). It is quite difficult to identify what kind of therapy is the most efective in patients with prefibrotic stage of PMF
Aims
To assess the effect of different therapy regimens on the course of the disease in patients with prefibrotic stage of PMF
Methods
We analyzed 32 Jak-positive patients with PMF (diagnosed according to the World Health Organisation Classification 2016). A total of 32 patients were included in this study. The age of subject ranged from 32 to 64 years. 8 patients were males and 24 - females. The mean follow-up was 42±9 month. Bone marrow biopsy control was performed in all the patients in 31±7 month. Estimation of spleen and liver size with ultrasound was made every 6 month. Patients were divided into three groups: 8 received 6±2 courses of cladribine and then interferon alfa, 10 were treated by interferon alfa and 14 received monotherapy by hydroxycarbamid
Results
Bone marrow biopsy control showed fibrotic stage of PMF in all groups of patients. However there was difference in spleen size. Initially there was no significant difference in spleen size in all groups of patients (range 257±34 by 109±31 mm). By the end of follow-up average size of spleen were 157±24 by 64±12 mm, 167±33 by 79±27 mm and 199±21 by 92±29 in first, second and third group respectively
Conclusion
Therapy with cladribine, hydroxycarbamide and interferon alfa doesn't influence the evolution of PMF. Cladribinein patients with prefibrotic stage of PMF significantly improves the quality of life due to more effective reduction of splenomegaly.
Session topic: 16. Myeloproliferative neoplasms - Clinical
Keyword(s): Cladribine, Myelofibrosis